drugset / Trial / NCT06515626
Genetically Modified T Cells Treating Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
To observe the safety, tolerability and initial effectiveness of gene modified T cell therapy in patients with malignant tumors in First Affiliated Hospital of Zhengzhou University, China.
Timeline
- Start
- 2024-08-18
- Primary completion
- 2025-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T cell reinfusion | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CAR-T cell reinfusion | Cell therapy | 1e+07 cells/kg | Intravenous |